Vision, Integrity, Expertise

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, acute radiation syndrome, and emerging and antibiotic resistant infectious disease.

 
* * Latest News Latest News
 
* * Relevant Publications Publications
 
* * Presentations Presentations

Therapeutic Applications of Innate Immune Modulation
October 9, 2017

Watch the presentation on YouTube


Innate Defense Regulators As An Agnostic Therapy To Treat Bacterial Infections And Fight Resistance
September 14, 2017

Watch the presentation on YouTube


Modulation of Innate Immunity in the Treatment of Inflammation-Driven and Infection-Driven Disease
July 13, 2017
Watch the presentation on YouTube


RiVax® Correlates of Immune Protection
Serum Antibody Profiling Following Vaccination Reveals a Correlate of Immunity to Ricin Toxin
April 25, 2017
View the presentation (pdf)

Show more >

* Presentations

Therapeutic Applications of Innate Immune Modulation
October 9, 2017

Watch the presentation on YouTube


Innate Defense Regulators As An Agnostic Therapy To Treat Bacterial Infections And Fight Resistance
September 14, 2017

Watch the presentation on YouTube


Modulation of Innate Immunity in the Treatment of Inflammation-Driven and Infection-Driven Disease
July 13, 2017
Watch the presentation on YouTube


RiVax® Correlates of Immune Protection
Serum Antibody Profiling Following Vaccination Reveals a Correlate of Immunity to Ricin Toxin
April 25, 2017
View the presentation (pdf)

Show more >

Our Clinical Trials

Learn more >

Partnering with Us

Learn more >